Applied Biosciences Corp.

Equities

APPB

US03815L1026

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 07:00:19 23/10/2023 pm IST			5-day change	1st Jan Change
0.0002 ^USD	-.--%		-.--%	-.--%

2020	Applied BioSciences Corp. Terminates Agreement to Offer Test Kits	CI
2020	Applied BioSciences Begins Offering Coronavirus Test Kit to the General Public to Combat Spread of COVID-19	CI

Applied Biosciences Corp. Reports Earnings Results for the Third Quarter Ended December 31, 2019

February 18, 2020 at 04:58 pm IST

Applied Biosciences Corp. announced earnings results for the third quarter ended December 31, 2019. For the third quarter, the company announced total revenue was USD 169,575 compared to USD 413,109 a year ago. Operating loss was USD 970,241 compared to USD 1.384 million a year ago. Net loss was USD 1.353 million compared to USD 1.891 million a year ago. Basic loss per share from continuing operations was USD 0.1 compared to USD 0.16 a year ago. For the nine months, total revenue was USD 625,306 compared to USD 472,509 a year ago. Operating loss was USD 2.272 million compared to USD 2.236 million a year ago. Net loss was USD 2.555 million compared to USD 2.397 million a year ago. Basic loss per share from continuing operations was USD 0.19 compared to USD 0.22 a year ago.

Latest news about Applied Biosciences Corp.

Applied BioSciences Corp. Terminates Agreement to Offer Test Kits	25/20/25	CI
Applied BioSciences Begins Offering Coronavirus Test Kit to the General Public to Combat Spread of COVID-19	31/20/31	CI
Applied Biosciences Corp. Announces Resignation of Raymond Urbanski as Chief Executive Officer and Director	19/20/19	CI
Applied Biosciences Corp. Reports Earnings Results for the Third Quarter Ended December 31, 2019	18/20/18	CI
Applied Biosciences Corp. Reports Earnings Results for the Second Quarter Ended September 30, 2019	15/19/15	CI
Pond Naturals Signs Agreement with Applied BioSciences to Sell its X10 Pet Supplement in the US alongside CBD-based Herbal Pet products	17/19/17	CI
Applied Biosciences Corp. Appoints Michael Beaubaire as Director	07/19/07	CI
Applied BioSciences Corp. Announces Resignation of John Brady as Director	17/19/17	CI
Applied Biosciences Corp. announced that it has received $0.25 million in funding from FirstFire Capital Management LLC	09/19/09	CI
Applied Biosciences Corp. announced that it expects to receive $0.5 million in funding from FirstFire Capital Management LLC	04/19/04	CI
Applied Biosciences Corp. Reports Earnings Results for the First Quarter Ended June 30, 2019	14/19/14	CI
Applied Biosciences Corp. Reports Earnings Results for the Full Year Ended March 31, 2019	02/19/02	CI
Applied Biosciences Corp. Auditor Raises 'Going Concern' Doubt	01/19/01	CI
Applied BioSciences Launches Champ Organics CBD Product Line	06/19/06	CI
Applied Biosciences Corp. Appoints Raymond Urbanski as Chief Executive Officer and Director	29/19/29	CI
Applied BioSciences Corp. Appoints Raymond W. Urbanski as Chief Executive Officer	07/19/07	CI
Applied Biosciences Corp. Appoints Scott Stevens as Director	20/19/20	CI
Applied BioSciences Announces Partnership with Boxing Heavyweight Champion Shannon Briggs	20/19/20	CI
Applied Biosciences Corp. Reports Revenue Results for the Third Quarter of 2019	18/19/18	CI
Applied Biosciences Corp. Reports Earnings Results for the Third Quarter Ended December 31, 2018	14/19/14	CI
Xiang-Qun Xie Joins Applied Biosciences Corp.'s Scientific Advisory Board	24/19/24	CI
Applied Biosciences Corp. acquired an unknown majority stake in Trace Analytics for $1.25 million.	09/19/09	CI
Applied Biosciences Corp. Enters Vape Inhaler Market	07/18/07	CI
Applied Biosciences Corp Expands Product Line and Launches Hemp-Derived CBD Product Pet Line Under the HerbalPet Brand	22/18/22	CI
Applied Biosciences Corp. announced that it expects to receive $1 million in funding from Triton Funds LLC	15/18/15	CI

Chart Applied Biosciences Corp.

Duration

Period

More charts

Company Profile

Applied BioSciences Corp. is a vertically integrated company that is focused on the development of science-driven cannabinoid therapeutics/biopharmaceuticals. The Company delivers cannabidiol (CBD) products as well as testing and analytics capabilities to its customers. It sells consumer products, including health and wellness creams, tinctures, edibles, confections, clothing, apparel, and other various branded products. Its various brands include Remedi, Remedi Plus, HerbalPet, Champ Organics and Equine Care. Its products are focused on the medical, bioceutical and pet health industries. The Company's subsidiaries include Applied Products LLC, Trace Analytics, Inc., and API Holdings, LLC, among others.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
APPLIED BIOSCIENCES CORP.	-.--%	4.28T
MODERNA, INC.	+33.63%	5.08TCr
IQVIA HOLDINGS INC.	-0.09%	4.28TCr
LONZA GROUP AG	+49.62%	4.2TCr
CELLTRION, INC.	-4.96%	2.95TCr
ICON PUBLIC LIMITED COMPANY	+11.18%	2.61TCr
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	1.91TCr
BIO-TECHNE CORPORATION	+8.61%	1.31TCr
MEDPACE HOLDINGS, INC.	+28.31%	1.22TCr
UNITED THERAPEUTICS CORPORATION	+24.73%	1.21TCr

Other Biotechnology & Medical Research